Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
C. Castellani (Genoa, Italy), N. Simmonds (London, United Kingdom), C. Colombo (Milan, Italy), N. Kinnman (Boston, United States of America), C. Desouza (Boston, United States of America), T. Thorat (Boston, United States of America), M. Chew (Boston, United States of America), K. Chandarana (Boston, United States of America), K. Van Der Ent (Utrecht, Netherlands). Respiratory microbiology outcomes from an observational study of ivacaftor in people with cystic fibrosis and non-G551D gating mutations (VOCAL). 2102

Member's Comments

No comment yet.

Related content which might interest you: Observational study of ivacaftor in people with cystic fibrosis and selected non-G551D gating mutations: final results from VOCAL Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation Source: Eur Respir J 2016; 47:1697-1705 Year: 2016 Clinical validity of functional respiratory imaging in cystic fibrosis: a cross-sectional study. Source: Virtual Congress 2021 – Lung function evaluation and assessment of airway diseases Year: 2021 Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 The German cystic fibrosis quality assurance project: clinical features in children and adults Source: Eur Respir J 2001; 17: 1187-1194 Year: 2001 The impact of genotype on clinical course of cystic fibrosis (CF) in adult patients Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Long-term non-invasive ventilation (NIV) in adults with cystic fibrosis (CF): a retrospective study Source: Eur Respir J 2004; 24: Suppl. 48, 544s Year: 2004 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 Assessment of the work of breathing (sWOB) within different functional and genetic groups in patients with cystic fibrosis (CF) Source: Annual Congress 2013 –New perspectives of lung function assessment in children Year: 2013 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Respiratory infections in young children with cystic fibrosis: A community-based longitudinal study Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 The study of expectant life of St-Petersburg patients with cystic fibrosis (CF) Source: Eur Respir J 2004; 24: Suppl. 48, 617s Year: 2004 STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013 Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 National survey of hearing assessment in patients with cystic fibrosis in the UK Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016